1. In this randomized, double-blind, phase three trial, progression-free survival was higher in patients treated with lorlatinib compared with crizotinib. ...
1. In this randomized, double-blind, phase three trial, progression-free survival was higher in patients treated with lorlatinib compared with crizotinib. ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.